Search
+
    SEARCHED FOR:

    GILEAD SCIENCES

    18 patent applications for HIV drug lenacapavir may delay affordable generics in India

    Gilead Sciences has filed 18 patent applications in India for lenacapavir, raising concerns among patient groups. They argue these applications may hinder the availability of affordable generic versions of the HIV drug. Consumer advocates have approached the patent office, seeking a rejection of these filings as they may constitute evergreening. If granted, these patents could remain valid until 2042, extending exclusive rights.

    Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginally

    Dr Reddy’s Laboratories reported a 36% year-on-year profit decline to Rs 913.4 crore in Q2 FY27, while revenue slipped 1.5%. North America weakness pressured performance, offset partly by growth in India and emerging markets, alongside biosimilar approvals and strategic partnerships.

    Dr Reddy's inks pact with Gilead for once-yearly HIV prevention drug lenacapavir

    Dr Reddy's Laboratories and Gilead Sciences have signed a licensing agreement. This pact involves investigational once-yearly lenacapavir for HIV prevention. The agreement facilitates manufacturing and supply planning for 120 countries. This collaboration builds upon a previous pact for twice-yearly lenacapavir.

    Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion

    Gilead will pay $115 per share in cash at the deal's closing, which is at a premium of 79% to the stock's last close. Kite Pharma, a unit ?of Gilead Sciences, was partnering with Arcellx ?to jointly develop and sell anito-cel, an experimental CAR-T therapy for multiple myeloma, a type of blood cancer.

    Gilead Sciences Inc (GILD) share price, Expedia Group Inc (EXPE) stocks make record-breaking jump. Details here

    US Stock Market indexes S&P 500, Nasdaq, and Dow Jones made weekly gains as Gilead Sciences Inc (GILD) and Expedia Group Inc (EXPE) stocks are rising.

    Emcure Pharmaceuticals partners with Gilead Sciences to produce HIV prevention drug Lenacapavir

    Emcure Pharmaceuticals has partnered with Gilead Sciences Ireland UC to manufacture and distribute generic lenacapavir for HIV prevention and treatment. This royalty-free agreement focuses on increasing access to the drug in 120 countries, especially resource-limited nations. Emcure aims to provide high-quality, low-cost HIV medication to improve health outcomes globally.

    The Economic Times
    BACK TO TOP